Damora Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
DMRA$24.07+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| ExhibitNumber | Exhibit Description | Incorporated by ReferenceHerein from Form or Schedule | Filing Date | SEC File / Reg. Number |
|---|---|---|---|---|
| 2.2† | Agreement and Plan of Merger, dated November 10, 2025, by and among the Registrant, Daylight Merger Sub I, Inc., Daylight Merger Sub II, LLC and Damora Therapeutics, Inc. | Form 8-K(Exhibit 2.1) | November 10, 2025 | 001-39655 |
| 3.1 | Amended and Restated Certificate of Incorporation of the Registrant. | Form 8-K (Exhibit 3.1) | November 4, 2020 | 001-39655 |
| 3.2 | Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (Reverse Stock Split). | Form 8-K(Exhibit 3.1) | September 5, 2024 | 001-39655 |
| 3.3 | Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (Authorized Share Increase). | Form 8-K(Exhibit 3.1) | February 10, 2026 | 001-39655 |
| 3.4 | Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (Name Change). | Form 8-K(Exhibit 3.1) | March 10, 2026 | 001-39655 |
| 3.5 | Certificate of Designation of Series A Non-Voting Convertible Preferred Stock. | Form 8-K (Exhibit 3.1) | October 7, 2024 | 001-39655 |
| 3.6 | Certificate of Designation of Series B Non-Voting Convertible Preferred Stock. | Form 8-K(Exhibit 3.1) | November 10, 2025 | 001-39655 |
| 3.7 | Certificate of Designation of Series C Non-Voting Convertible Preferred Stock. | Form 8-K(Exhibit 3.2) | November 10, 2025 | 001-39655 |
| 3.8 | Certificate of Correction to the Certificate of Designation of the Series C Non-Voting Convertible Preferred Stock. | Form 8-K/A(Exhibit 3.3) | December 9, 2025 | 001-39655 |
| 3.9 | Amended and Restated By-laws of the Registrant. | Form 8-K (Exhibit 3.2) | November 4, 2020 | 001-39655 |
| 3.10 | Certificate of Amendment to Amended and Restated By-laws of the Registrant. | Form 10-K(Exhibit 3.5) | March 19, 2025 | 001-39655 |
| 10.1# | Damora Therapeutics, Inc. 2026 Equity Incentive Plan. | Form S-8 (Exhibit 99.1) | March 20, 2026 | 333-294492 |
| 10.2#* | Form of Option Award Agreement under the 2026 Equity Incentive Plan. | |||
| 10.3# | Damora Therapeutics, Inc. 2026 Employee Stock Purchase Plan. | Form S-8 (Exhibit 99.2) | March 20, 2026 | 333-294492 |
| 31.1* | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |||
| 31.2* | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |||
| 32.1*† | Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101.INS | Inline XBRL (extensible Business Reporting Language) Instance Document |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
- Filed herewith.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.